Rescue more patients with gastric cancer, the new triple anti-cancer therapy results are optimistic

About 20% of advanced gastric cancer or gastroesophageal junction adenocarcinomas overexpress human epidermal growth factor receptor 2 (HER2).

In fact, trastuzumab is a type of HER2 antibody, which can enhance the cross-presentation of HER2 through dendritic cells, thereby stimulating HER2-specific T cell responses.

Based on these characteristics, in recent years, researchers have also tried to introduce immunotherapy on the basis of existing first-line therapies to increase the therapeutic effect

With the repeated verification of mouse experiments, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College have promoted related phase 2 clinical trials.

In the latest issue of "Nature", the research team once again brought some results from a randomized, double-blind Phase 3 trial

Overall, the response rates of patients in the triple-group and placebo groups were 74.

Among the volunteers who responded to the treatment, patients in the triple combination group also had a longer response time.

According to research observations, there is not much difference in the incidence of side effects between the two groups.

The paper pointed out that compared with the current first-line therapy, the phase 3 clinical trial results show that the addition of pembrolizumab can further improve the clinical treatment effect of unresectable or metastatic HER2-positive gastric cancer and gastroesophageal junction adenocarcinoma

This kind of triple therapy has a deeper level of response and a longer duration, and the safety is still controllable

Note: The original text has been deleted

Reference materials:

[1] Yelena Y.